Drug Trial Radar · NCT06475274
A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
Aug 26, 2024
Primary completion
Sep 11, 2025
Study completion Sep 11, 2025
Sponsor
- Lead sponsor
- Guard Therapeutics ABIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to identify the optimal dose of RMC-035 for protection of long-term renal function in adult patients undergoing cardiac surgery who are at high risk of kidney injury. It will also learn about the safety of RMC-035. The main question it aims to answer is: * Does RMC-035 protect the function of kidneys after surgery? * Is RMC-035 safe? Researchers will compare RMC-035 in high dose, RMC-035 in low dose and placebo to see if * Kidney function better for participants treated with any of the RMC-035 doses? * What medical problems do participants have when receiving RMC-035? Participants will * Receive 3 doses of RMC-035 or placebo: at the beginning of surgery, end of surgery and 24h after surgery * Have extra checkups and tests during their hospital stay * Visit the clinic at two extra occasions at 60 days and 90 days after surgery for checkups and tests
Conditions
- Kidney Injury Following Open-Chest Cardiac Surgery
Interventions
RMC-035Drug
Protein, a recombinant variant of A1M. Concentrate for solution for infusion.
PlaceboDrug
Identical to RMC-035 intervention devoid of the active substance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in eGFR at Day 90 (the two arms of RMC-035 pooled compared against placebo)Time frame: 90 days
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
Research site 4
Montreal, Canada
Research site 5
Montreal, Canada
Research site 2
Québec, Canada
Research site 3
Saint John, Canada
Research site 1
Toronto, Canada
Research site 1
Hradec Králové, Czechia
Research site 2
Prague, Czechia
Research site 5
Dresden, Germany
Research site 3
Essen, Germany
Research site 6
Giessen, Germany
Research site 4
Halle, Germany
Research site 2
München, Germany
Research site 1
Münster, Germany
Research site 3
Barcelona, Spain
Research site 4
Córdoba, Spain
Research site 1
Madrid, Spain
Research site 2
Madrid, Spain
Research site 6
Pamplona, Spain
Research site 5
Santiago de Compostela, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.